MBX
SHORT CANDIDATEMeanRevComposite
34.60
Technical
91.10
Fundamental
15.80
Rank
—
Price
62.92
Hurst
0.25
As of
Jul 20, 2026
Daily
MBX Biosciences, Inc.
HealthcareBiotechnologyMBX Biosciences is a clinical-stage biotech company developing peptide-based treatments for metabolic and endocrine conditions. Its main product candidates include Canvuparatide, currently in Phase 3 testing for chronic hypoparathyroidism; Imapextide, in Phase 2 development for post-bariatric hypoglycemia; and MBX 4291, in preclinical studies targeting obesity. Founded in 2018, the company is headquartered in Carmel, Indiana.
Market cap
$2.7B
P/E (trailing)
—
P/E (forward)
-14.05
PEG ratio
—
Dividend yield
0.00%
Beta
0.10
52w range
20.21 – 72.64
Return on equity
-33.17%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 55.87 (+154.4%) · range 20.61–70.70
Cycle position
45/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 33 · NOT READY · exit proximity 0
Conviction
19/ 100 · maturity 0%
Buildup.333
EMA entry setup.4233
Fundamentals.2516
Volume profile
POC
31.12
Price vs POC
+79.5%
Overhead supply
46%
Runway
+2.0%
Value area 28.89–61.03 · 46% of 120d volume overhead · moderate overhead
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +13.49% | +17.56% | mature |
| 40d | +1.56% | +17.56% | mature |